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We have also shown in a recent twin study that the rate of
progression of knee OA has a strong heritable basis.
Reports of significant associations for candidate genes for com-
mon forms of OA of the knee and hip now include over 50 genes
– and over a dozen have now been replicated independently.
These include VDR, ERG, CILP, Col2A1, AACT, BMP-2, FRZB,
ADAM12, IL-1, IL-1-RA, ASPN, LRCH1, matrillin3, COMP, and
OPG. Linkage studies using families and affected sib pairs have
to date shown a number of significant replicated loci, especially
areas on chromosome 2q and Chromosome 19.
OA is best studied genetically by dividing the phenotype into
its constituent parts and by studying intermediate phenotypes,
which may operate independently or together in clusters deter-
mined by pleiotropic genes. For example Cartilage loss at the
fingers or knee medial compartment or serum COMP or bone
turnover marker levels have all been shown to be heritable.
In conclusion, OA is a strongly genetic disease, which is likely
to be a complex polygenic disorder that may differ genetically by
gender site and race. We now have more than a dozen replicated
genes and are close to being able to use these clinically for both
diagnosis and clinically to predict progression and prognosis.
Understanding how the individual genes influence the many
intermediate processes is likely to be a fruitful avenue to provide
insight into disease pathways and potential new drug targets.
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TISSUE ENGINEERING BASED ON MUSCLE-DERIVED
STEM CELLS: POTENTIAL APPLICATIONS FOR TISSUE
REGENERATION
Johnny Huard
Summary: Members of my laboratory have isolated various pop-
ulations of myogenic cells from the postnatal skeletal muscle of
normal mice on the basis of the cells’ adhesion characteristics,
proliferation behavior, and myogenic and stem cell marker ex-
pression profiles. Although most of these cell populations have
displayed characteristics similar to those of satellite cells, we
also have identified a unique population of muscle-derived stem
cells (MDSCs). MDSCs exhibit long-term proliferation and high
self-renewal rates and can differentiate toward various lineages,
both in vitro and in vivo. The transplantation of MDSCs, in
contrast to that of other myogenic cells, has improved the ef-
ficiency of dystrophic muscle regeneration and the delivery of
dystrophin to dystrophic muscle. The ability of MDSCs to pro-
liferate in vivo for an extended period of time, combined with
their capacity to exhibit self-renewal, multipotent differentiation,
and transplantation. Recent studies performed by members of
my laboratory have shown that transplantation of female MDSCs
(F-FMSCs) rather than male MDSCs (M-MDSCs) significantly
improves skeletal muscle regeneration despite the similar myo-
genic and stem cell marker expression by both cell types. I will
explain the increased muscle regeneration efficiency exhibited
by F-MDSCs. My presentation will also address the influence of
environmental cues within dystrophic or injured skeletal muscle
on the differentiation of MDSCs into fibrotic cells. I will discuss
potential strategies by which to prevent scar tissue formation
within injured muscle by blocking TGF-β1 activity. I then will dis-
cuss the use of MDSCs in gene therapy and tissue engineering
applications designed to improve bone and articular cartilage
healing through the genetic modification of MDSCs to express
osteogenic proteins (BMP2 and -4) and the angiogenic factor
VEGF. I will also outline in my presentation new results obtained
with human muscle derived stem cells, which we believe will
open new avenues by which researchers could use muscle stem
cell-based gene therapy and tissue engineering to improve tissue
regeneration.
20
NEW THERAPEUTIC STRATEGIES AND AGENTS WITH
STRUCTURE MODIFYING POTENTIAL IN
OSTEOARTHRITIS
Jean-Pierre Pelletier
Over the last decade, there have been several interesting ad-
vances in the treatment of osteoarthritis (OA). A clearer under-
standing of the pathophysiology of this disease has facilitated
the development of new approaches for treatments aimed at
specifically and effectively retarding the progress of the disease.
Several new classes of molecules that inhibit one or more OA
pathophysiological processes are under evaluation for their po-
tential to alter the degenerative process.
Osteoarthritis can be described primarily as the degradation and
loss of articular cartilage accompanied by subchondral bone
remodeling, osteophyte formation, and synovial membrane in-
flammation. The most attractive recent findings are the data
pointing to an association between inflammation and disease
appearance and progression. There is significant interest in new
agents that have the potential to reduce or stop the progression
of structural changes observed in OA. Such agents offer great
promise and are likely to lead to very significant changes in
therapeutic approaches in the near future.
The use of NSAIDs or COX-2 selective inhibitors has shown that
PGE2 inhibition alone has not proven to delay the natural history
of progressive OA. Other lipid mediators, including leukotrienes
(LT), could play a major role in the development and persistence
of the inflammatory process, and it is now clear that PG and LT
have complementary effects. Recent studies have also revealed
that LTB4 potently stimulated the release of pro-inflammatory
cytokines, such as IL-1β and TNF-α in human OA synovial
membrane. Thus, the failure of NSAIDs to impact OA progression
in these tissues could be due to the fact that inhibiting only the
COX pathways leads to a shunt to LT production. Based on this
concept, it is hypothesized that blocking production of both LT
and PGE2 could have a synergistic effect in achieving an optimal
or a wider spectrum of anti-inflammatory activity.
Pro-inflammatory cytokines are likely responsible for some of
the signs and symptoms as well as structural changes present
in OA patients. There exists a number of ways by which the
production or activity of cytokines could be reduced. These will
be reviewed in brief. The action of cytokines can be reduced at
the cell membrane level by decreasing the membrane receptor
level or by the use of receptor antagonists or soluble receptors.
Blocking the intracellular signaling pathways is another way to
reduce the action of the cytokine.
The natural IL-1 receptor antagonist (IL-1Ra) is capable of re-
ducing several cartilage catabolic processes that are IL-1β de-
pendent. In vivo studies in animal models have demonstrated
that the intra-articular injection of IL-1Ra could block the action
of IL-1β and reduce disease progression. Data from early phase
clinical trials in knee OA patients have also shown interesting
symptomatic effects of IL-1Ra.
Another interesting target for controlling the activity of the IL-1
system is the IL-1 converting enzyme (ICE)/caspase-1, an en-
zyme which is responsible for the conversion of the proform of IL-
1β into its active (mature) form. Usage of ICE inhibitor also repre-
sents another interesting potential target for the treatment of OA.
The role of proteases in the degradation of the extracellular
matrix of cartilage in OA has been well documented, and met-
alloproteases (MMPs) are believed to play a major role in this
process. Inhibition of the synthesis/activity of these enzymes as
a treatment for OA has been the focus of intensive research.
To date, the most promising strategy is still the use of chemical
molecules that can block the activity of MMPs. A number of
these compounds that have a broad range of MMP activities
have already been tested in clinical trials. From these trials, we
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have learnt that MMP inhibitors could produce side effects and
have not yet demonstrated a major reduction in the progression
of the disease. Certain MMPs, such as MMP-13 and ADAMTS
proteases, such as ADAMTS5, have been selected as being
the most attractive targets for the treatment of OA. The main
reason(s) for choosing selective inhibition, instead of a broad
inhibition, is based on the hypothesis that by doing so a certain
number of side effects that could potentially be related to a broad
MMP inhibition can be avoided.
Another possible way to inhibit the effect of certain catabolic
factors lies in the inhibition of certain intracellular signaling path-
ways such as the protein kinase cascades. The kinases, which
constitute the most appealing targets, include p38, ERK 1/2, and
SAPK/JNK. A recent study showed that an orally active ERK 1/2
selective inhibitors could very significantly and effectively reduce
the progression of lesions in the rabbit OA model by inhibiting the
synthesis of catabolic factors, such as MMPs. Another emerging
field of research focuses on the development of molecules that
can inhibit the binding of the transcription factors at the DNA
level. The major transcription factors targeted for the inhibition of
cytokines and MMP synthesis are NF-κB and AP-1.
On the subject of cell signaling, another interesting target are the
ligands to a group of nuclear transcription factors, the peroxisome
proliferator-activated receptor gamma (PPARγ), which act as
anti-inflammatory agents. In vivo, synthetic PPARγ ligands were
found to protect against structural damages in the collagen-
induced arthritis model and in OA models.
OA structural changes also involve modifications in the mor-
phology of the surrounding bone. Subchondral bone remodeling
is a well-recognized manifestation of OA. New data underline
the concept that abnormal subchondral bone cell functions may
contribute to the onset/progression of OA. Therapeutic effects
of drugs that prevent the abnormal metabolism of subchondral
osteoblasts on the progression of OA lesions is currently of major
interest in the context of future DMOAD development.
Several new pharmacologic DMOAD agents are under inves-
tigation. Preclinical results are promising and demonstrate the
possibility of retarding or inhibiting the progression of joint tissue
structural changes. The tools to study such effects in the human
population remain unsatisfactory. Existing radiologic methods
are useful but this methodology is imperfect and time consum-
ing. Faster and more accurate methods are needed to improve
the investigation of new drugs that have the potential to modify
the progression of OA.
In conclusion, several interesting new approaches for the treat-
ment of this disease are now being explored. New classes of
molecules that inhibit one or more of the disease processes of
OA are under evaluation for their potential to alter the degenera-
tive process
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BIOREACTORS FOR CARTILAGE TISSUE
ENGINEERING
Ivan Martin
Introduction: Recent animal experiments have demonstrated
that engineered cartilage tissues generated by culturing chon-
drocytes into 3D scaffolds provide functional templates for the
orderly repair of critically sized osteochondral lesions. In order to
reproducibly generate functional cartilage tissues starting from
adult human cells, efforts have to be directed not only to the
identification of stimulatory biochemical factors, but also to the
development and use of controlled bioreactor systems, applying
defined regimes of physical forces. In this work, we present some
examples on the use of bioreactors for processes that are key for
engineering of 3D cartilage tissues based on cells and scaffolds,
namely the chondrocyte seeding into porous scaffolds, their ef-
ficient nutrition, and the pysical conditioning of the developing
tissues.
Chondrocyte seeding and culture under perfusion: In the cell
seeding process, cells must be utilized with maximum efficiency
to minimize the biopsy size needed and/or the extent of cell
expansion, and must be dispersed uniformly throughout the
scaffold volume to form the basis for uniform tissue formation.
To overcome limitations associated with the most commonly
employed seeding techniques, we developed a bioreactor for
the automated cell seeding of three-dimensional scaffolds by
continuous perfusion of a cell suspension through the scaffold
pores in oscillating directions. Perfusion seeding of chondrocytes
into Polyactive foams (IsoTis OrthoBiologics, NL) or Hyaff?-11
non-woven meshes (Fidia Advanced Biopolymers, IT) resulted
in the highest fraction of viable cells within the foam pores, the
greatest efficiency of seeding and the highest uniformity of cell
distribution in comparison to the typically used static and spinner
flask methods [1].
Constructs uniformly seeded by perfusion and then cultured
statically for 2 weeks were highly heterogeneous in structure,
consisting of a layer of cells and matrix at the periphery and an
essentially void interior region. Instead, constructs cultured under
prolonged perfusion were remarkably homogeneous, containing
a uniform distribution of both cells and matrix throughout the
cross-section [2].
Physical conditioning of cartilagel constructs: Application of
dynamic compression to cell-polymer constructs could poten-
tially improve the development of cartilaginous tissue in vitro.
We exposed human articular chondrocytes-based cartilaginous
constructs at different stages of maturation, as defined by the
glycosaminoglycan (GAG) content, to intermittent compressive
deformation for 3 days. Compression-induced changes in GAG
synthesis and accumulation were positively correlated to the
GAG content prior to loading, such that compression was stimu-
latory only for the most developed constructs. Therefore, under
our experimental conditions, cyclic loading appears to be appli-
cable for the enhancement of cartilaginous tissue development
only in the late phases of tissue regeneration [3]. Our results
also point out the possible use of bioreactors applying defined
regimes of physical forces as a quality control tool for engineered
cartilage, with the goal of defining when the tissues are suffi-
ciently developed for immediate load bearing after implantation.
Conclusion: The reviewed studies indicate that bioreactors en-
able generation of cartilaginous tissue constructs and may con-
tribute to understand the function of specific chemico-physical
culture parameters on cartilage tissue development. In the fu-
ture, bioreactors are expected to efficiently translate laboratory-
to inductrial-scale cartilage tissue engineering, possibly providing
an economically viable approach to the automated manufacture
of functional cartilage grafts for broad clinical use [4].
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PAIN IN OSTEOARTHRITIS
Hans-Georg Schaible
Purpose: The most dominant subjective problem of the patient
suffering from osteoarthritis is pain. In most cases pain is local-
ized to the joint with OA but it can be referred to other joints.
OA pain varies in intensity and is usually worsened by exercise
